Table 3.
Baseline characteristics of patients with no history of previous HCC according to HCC occurrence after DAA therapy
| Characteristics | Patients without occurrence of HCC | Patients with occurrence of HCC | P‐value |
|---|---|---|---|
| Age (years) | 70.5 (16–88) | 76.0 (65–84) | 0.051 |
| Sex (female/male) | 119 (51.1%)/107 (48.9%) | 6 (85.7%)/1 (14.3%) | 0.126 |
| HCV genotype (1b/2a or 2b) | 165/61 | 6/1 | 0.678 |
| Body mass index (kg/m2) | 22.4 (15.4–32.9) | 23.5 (18.1–31.5) | 0.171 |
| Serum albumin (g/dL) | 4.1 (2.2–4.9) | 3.8 (2.8–4.4) | 0.307 |
| Total bilirubin (mg/dL) | 0.72 (0.3–2.5) | 0.97 (0.6–1.8) | 0.031 |
| Alanine aminotransferase (IU/L) | 34.1 (10–299) | 25.0 (17–106) | 0.616 |
| Aspartate aminotransferase (IU/L) | 37.7 (16–224) | 43.0 (28–106) | 0.194 |
| Gamma‐glutamyl transpeptidase (IU/L) | 30.7 (8–521) | 22.0 (13–146) | 0.315 |
| Platelet count (×103/μL) | 156 (14–351) | 118 (48–204) | 0.107 |
| α‐Fetoprotein (ng/mL) | 4.2 (0.9–172.3) | 6.4 (2.5–50.5) | 0.099 |
| Liver stiffness (m/s) | 1.33 (0.67–4.35) | 2.06 (1.40–4.00) | 0.005 |
DAA, direct‐acting antiviral; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.